TCT-404 Trends of Drug Coated Balloon Use in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry

Document Type

Conference Proceeding

Publication Date

10-29-2024

Publication Title

J Am Coll Cardiol

Abstract

Background: There is limited information on the use of drug-coated balloons (DCBs) in chronic total occlusion (CTO) percutaneous coronary artery intervention (PCI). Methods: We evaluated the frequency of DCB use in an international registry (PROGRESS-CTO [Prospective Global Registry for the Study of Chronic Total Occlusion Intervention]). Results: Among 7,893 patients, DCBs were used in 200 cases (2.5%; paclitaxel coated in 91.8%, sirolimus coated in 8.2%) with increasing frequency over time (Figure). Mean patient age was 64 ± 10 years, 80.1% were men, and 24.5% had prior coronary artery bypass graft surgery. CTOs requiring the use of DCBs were less complex with a lower J-CTO score (Multicenter CTO Registry of Japan) (2.1 ± 1.2 vs 2.3 ± 1.2; P = 0.008), higher prevalence of in-stent restenosis (34.2% vs 15.5%; P < 0.001), and less moderate to severe calcification (32.3% vs 41.7%; P = 0.010) and tortuosity (19.3% vs 25.9%; P = 0.045). Lesions requiring DCBs were more frequently located in the right coronary artery (47.9%) and left anterior descending artery (34.0%). The mean number of DCBs was 1.3 ± 0.6 per PCI, with a mean diameter of 3.3 ± 2.4 mm, and mean length of 34.4 ± 18.0 mm. A hybrid strategy was more frequently used (59.0%) than a DCB-only strategy. The primary reason for DCB use was in-stent restenosis (53.8%) followed by investment procedure (33.9%) and side branch treatment (12.3%). The most common successful CTO crossing technique was antegrade wiring (71.7%) followed by retrograde (16.2%) and antegrade dissection and re-entry (8.1%). Technical and procedural success and the incidence of major cardiac adverse events were similar in both groups. [Formula presented] Conclusion: DCB are increasingly being used in CTO PCI and are associated with high success and low complication rates. Categories: CORONARY: Drug-Eluting Balloons and Local Drug Delivery.

Volume

84

Issue

18

First Page

B116

Last Page

B117

Share

COinS